- Home
- ADUR vs ACIU Comparison
ADUR vs ACIU Comparison
Compare ADUR & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADUR
- ACIU
- Stock Information
- Founded
- ADUR 2011
- ACIU 2003
- Country
- ADUR Canada
- ACIU Switzerland
- Employees
- ADUR N/A
- ACIU N/A
- Industry
- ADUR
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- ADUR
- ACIU Health Care
- Exchange
- ADUR NYSE
- ACIU Nasdaq
- Market Cap
- ADUR 162.6M
- ACIU 189.1M
- IPO Year
- ADUR N/A
- ACIU 2016
- Fundamental
- Price
- ADUR $11.75
- ACIU $2.07
- Analyst Decision
- ADUR Strong Buy
- ACIU Strong Buy
- Analyst Count
- ADUR 1
- ACIU 1
- Target Price
- ADUR $48.00
- ACIU $12.00
- AVG Volume (30 Days)
- ADUR 307.6K
- ACIU 125.1K
- Earning Date
- ADUR 01-01-0001
- ACIU 08-05-2025
- Dividend Yield
- ADUR N/A
- ACIU N/A
- EPS Growth
- ADUR N/A
- ACIU N/A
- EPS
- ADUR N/A
- ACIU N/A
- Revenue
- ADUR $179,327.00
- ACIU $32,014,254.00
- Revenue This Year
- ADUR N/A
- ACIU N/A
- Revenue Next Year
- ADUR N/A
- ACIU $533.21
- P/E Ratio
- ADUR N/A
- ACIU N/A
- Revenue Growth
- ADUR N/A
- ACIU 91.20
- 52 Week Low
- ADUR $3.25
- ACIU $1.43
- 52 Week High
- ADUR $12.40
- ACIU $4.26
- Technical
- Relative Strength Index (RSI)
- ADUR N/A
- ACIU 55.57
- Support Level
- ADUR N/A
- ACIU $2.00
- Resistance Level
- ADUR N/A
- ACIU $2.15
- Average True Range (ATR)
- ADUR 0.00
- ACIU 0.13
- MACD
- ADUR 0.00
- ACIU -0.01
- Stochastic Oscillator
- ADUR 0.00
- ACIU 80.92
About ADUR ADURO CLEAN TECHNOLOGIES INC
Aduro Clean Technologies Inc is a developer of patented water-based technologies to chemically recycle plastics and transform heavy crude and renewable oils into feedstocks and higher-value fuels. The company's technology activates unique properties of water in a chemistry platform that operates at relatively low temperatures and costs.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.